• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Re-Authorization of the Sickle Cell Treatment Act passes Through the House of Representatives

On Monday, February 26, 2018, the U.S. House of Representatives considered and passed H.R. 2410, the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act, which was introduced on May 11, 2017, by Representative Danny Davis (D-IL).

H.R. 2410 would authorize the Secretary of Health and Human Services to conduct surveillance and collect data on the prevalence of sickle cell disease (SCD). In addition, the bill would authorize the Secretary to develop public health initiatives that support community-based organizations in education activities and to support regional and state health departments in testing to identify SCD.

“This is a major victory for the sickle cell community,” said Sonja L. Banks, Sickle Cell Disease Association of America, Inc. (SCDAA) President. “It has been a long journey to get to this momentous occasion. SCDAA has worked tirelessly on the Treatment Act. We are so grateful for the ongoing support from Congressman Danny Davis and Congressman Michael Burgess (R-TX) for co-sponsoring this important legislation in the U.S. House of Representatives. We also want to thank the Congressional Sickle Cell Caucus, including G.K. Butterfield (D-NC) for standing alongside the sickle cell community.”



expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.